UK drug regulator seizes illegal weight-loss drugs
- Feb 28
- 2 min read
The Medicines and Healthcare products Regulatory Agency (MHRA) has seized more than 2,000 doses of illegal weight-loss medicines during an operation targeting an unlicensed manufacturing facility in the UK.
The enforcement action forms part of an ongoing MHRA crackdown on the illegal production and supply of weight-loss drugs, which has intensified alongside rising public demand for injectable treatments. Officers also recovered suspected pharmaceutical ingredients, packaging materials, and manufacturing equipment during the operation.
According to the MHRA, the seized products were not authorised for use in the UK and were being produced outside regulated supply chains. This means there were no assurances about their safety, quality, or effectiveness. The agency confirmed that the medicines may have been destined for online sale, where unregulated weight-loss products are increasingly marketed directly to consumers.
The regulator has warned repeatedly that illegally manufactured weight-loss medicines pose serious health risks. Products produced in unlicensed facilities may contain incorrect dosages, contaminated ingredients, or entirely different substances from those listed on the packaging. In injectable products, poor manufacturing standards also raise the risk of infection, abscesses, and systemic illness.
This latest seizure follows earlier MHRA enforcement actions against illegal suppliers of weight-loss drugs, including operations linked to online pharmacies and social media sales. The agency has noted a clear rise in criminal activity associated with these medicines, driven by shortages, high private prescription costs, and increased public interest in rapid weight loss.
The MHRA’s Criminal Enforcement Unit works alongside other law enforcement agencies to identify and disrupt illegal manufacturing and supply networks. The regulator has stressed that this activity is not limited to small-scale sellers but increasingly involves organised operations with access to equipment, packaging, and distribution channels.
Patients are advised that legitimate weight-loss medicines should only be obtained through regulated routes, following appropriate clinical assessment and prescribing. Medicines sold without prescription, particularly online, may not meet UK safety standards even if they appear professionally packaged.
The MHRA continues to urge the public to report suspected illegal medicines and side effects through the Yellow Card scheme. It has also reiterated that anyone experiencing symptoms after using unregulated weight-loss products should seek medical advice promptly.
As demand for weight-loss treatments continues to grow, regulators have indicated that enforcement activity will remain a priority, with further investigations and seizures expected.